Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

@article{Shin2001PhaseIS,
  title={Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.},
  author={Dong M Shin and Fadlo R. Khuri and Bonnie S. Glisson and Lawrence Ginsberg and Vassiliki Papadimitrakopoulou and Gary L Clayman and Jae Jin Lee and K. Kian Ang and Scott Michael Lippman and Waun Ki Hong},
  journal={Cancer},
  year={2001},
  volume={91 7},
  pages={
          1316-23
        }
}
BACKGROUND In the current study the authors assessed the antitumor activity (including response rate, duration of response, and survival) and toxicity profile (including anorexia, fatigue, emesis, and peripheral neuropathy) of a combination of paclitaxel, ifosfamide, and carboplatin (TIC) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial hypothesis was that the TIC therapeutic index would be as high as that of paclitaxel, ifosfamide, and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Similar Papers

Loading similar papers…